多发性骨髓瘤的移植后维持治疗：不断变化的格局
Posttransplant maintenance therapy in multiple myeloma: the changing landscape.
作者信息
Sengsayadeth S, Malard F, Savani B N, Garderet L, Mohty M
机构信息
Section of Hematology and Stem Cell Transplant, Vanderbilt Ingram Cancer Center, Nashville, TN, USA.
Department of Haematology, Saint Antoine Hospital, University Pierre and Marie Curie, and INSERM UMRs 938, Paris, France.
出版信息
Blood Cancer J. 2017 Mar 24;7(3):e545. doi: 10.1038/bcj.2017.23.
Abstract
Transplant-eligible patients with multiple myeloma (MM) now have extended survival after diagnosis owing to effective modern treatment strategies that include new agents in induction therapy, autologous stem cell transplant (ASCT), consolidation therapy and posttransplant maintenance therapy. Standard of care for newly diagnosed, fit patients includes ASCT and, often nowadays, posttransplant maintenance. Several large studies have shown the efficacy of maintenance with thalidomide, lenalidomide and bortezomib in the treatment scheme of MM with regards to prolonging progression-free survival and, to a lesser degree, overall survival. Herein we discuss the data currently available to support the use of maintenance therapy in patients after ASCT as well as the newer available agents that may be a part of its changing landscape in the years to come.
摘要
由于有效的现代治疗策略，包括诱导治疗中使用新药物、自体干细胞移植（ASCT）、巩固治疗和移植后维持治疗，符合移植条件的多发性骨髓瘤（MM）患者在诊断后的生存期得以延长。新诊断的健康患者的标准治疗包括ASCT，如今还常常包括移植后维持治疗。多项大型研究表明，在MM治疗方案中使用沙利度胺、来那度胺和硼替佐米进行维持治疗，在延长无进展生存期方面有效，在一定程度上也能延长总生存期。在此，我们讨论目前可支持在ASCT后患者中使用维持治疗的数据，以及未来几年可能成为其不断变化格局一部分的新型可用药物。
相似文献
1
Posttransplant maintenance therapy in multiple myeloma: the changing landscape.多发性骨髓瘤的移植后维持治疗：不断变化的格局
Blood Cancer J. 2017 Mar 24;7(3):e545. doi: 10.1038/bcj.2017.23.
2
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.来那度胺联合化疗与自体移植，随后来那度胺联合泼尼松与来那度胺维持治疗多发性骨髓瘤患者：一项随机、多中心、3 期试验。
Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.
3
Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.来那度胺：ASCT 后作为维持治疗在新诊断多发性骨髓瘤中的应用评价。
Drugs. 2017 Sep;77(13):1473-1480. doi: 10.1007/s40265-017-0795-0.
4
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma.多发性骨髓瘤患者自体干细胞移植后硼替佐米维持治疗的结果
Biol Blood Marrow Transplant. 2017 Feb;23(2):262-268. doi: 10.1016/j.bbmt.2016.11.010. Epub 2016 Nov 14.
5
Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin.多发性骨髓瘤自体移植后巩固治疗的两项连续研究结果：沙利度胺、地塞米松和克拉霉素或来那度胺、地塞米松和克拉霉素。
Acta Haematol. 2017;137(3):123-131. doi: 10.1159/000455937. Epub 2017 Mar 30.
6
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.适合自体移植的初诊多发性骨髓瘤患者维持治疗策略的进展。
Expert Rev Hematol. 2020 Dec;13(12):1333-1347. doi: 10.1080/17474086.2020.1839886. Epub 2020 Oct 26.
7
Risk adapted post-transplant maintenance in multiple myeloma.多发性骨髓瘤的风险适应性移植后维持治疗。
Expert Rev Hematol. 2019 Feb;12(2):107-118. doi: 10.1080/17474086.2019.1576521.
8
Lenalidomide in multiple myeloma.来那度胺治疗多发性骨髓瘤
Expert Rev Anticancer Ther. 2015 May;15(5):491-7. doi: 10.1586/14737140.2015.1033407. Epub 2015 Apr 5.
9
Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma.来那度胺用于日本多发性骨髓瘤患者移植后巩固和维持治疗。
Anticancer Res. 2013 Dec;33(12):5681-5.
10
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.硼替佐米联合沙利度胺和地塞米松与沙利度胺和地塞米松作为新诊断多发性骨髓瘤患者双自体干细胞移植前诱导治疗和巩固治疗的比较：一项随机 3 期研究。
Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9.
引用本文的文献
1
Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis.多发性骨髓瘤患者行第二次自体造血细胞移植后的维持治疗。一项 CIBMTR 分析。
Bone Marrow Transplant. 2022 Jan;57(1):31-37. doi: 10.1038/s41409-021-01455-y. Epub 2021 Oct 4.
2
Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma.新诊断多发性骨髓瘤自体干细胞移植后的维持治疗策略
Clin Hematol Int. 2020 May 20;2(2):59-68. doi: 10.2991/chi.d.200502.001. eCollection 2020 Jun.
3
A Qualitative Study of the Experiences of Living With Multiple Myeloma.多发性骨髓瘤患者生存体验的定性研究。
Oncol Nurs Forum. 2021 Mar 1;48(2):151-160. doi: 10.1188/21.ONF.151-160.
4
Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco-economic assessment.来那度胺作为自体干细胞移植后多发性骨髓瘤患者的维持治疗：药物经济学评估。
Eur J Haematol. 2020 Nov;105(5):635-645. doi: 10.1111/ejh.13497. Epub 2020 Sep 12.
5
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.TOURMALINE-MM3 研究中移植后伊沙佐米维持治疗多发性骨髓瘤的不良事件管理。
Ann Hematol. 2020 Aug;99(8):1793-1804. doi: 10.1007/s00277-020-04149-5. Epub 2020 Jul 1.
6
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.微小残留病阴性和来那度胺维持治疗与多发性骨髓瘤的更好生存结果相关。
Bone Marrow Transplant. 2020 Jun;55(6):1137-1146. doi: 10.1038/s41409-020-0791-y. Epub 2020 Jan 28.
7
Productivity losses in patients with newly diagnosed multiple myeloma following stem cell transplantation and the impact of maintenance therapy.新诊断多发性骨髓瘤患者干细胞移植后生产力损失和维持治疗的影响。
Eur J Haematol. 2019 Oct;103(4):393-401. doi: 10.1111/ejh.13298. Epub 2019 Aug 12.
8
The pharmacologic management of multiple myeloma in older adults.老年人多发性骨髓瘤的药物治疗管理。
Expert Opin Pharmacother. 2019 May;20(7):887-902. doi: 10.1080/14656566.2019.1577822. Epub 2019 Feb 20.
9
Navigating the treatment landscape in multiple myeloma: which combinations to use and when?多发性骨髓瘤治疗领域探索：何时及如何使用哪些联合方案？
Ann Hematol. 2019 Jan;98(1):1-18. doi: 10.1007/s00277-018-3546-8. Epub 2018 Nov 23.
10
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.造血干细胞移植治疗多发性骨髓瘤的应用：梅奥多发性骨髓瘤分层与风险适应性治疗（mSMART）共识声明。
Bone Marrow Transplant. 2019 Mar;54(3):353-367. doi: 10.1038/s41409-018-0264-8. Epub 2018 Jul 9.
本文引用的文献
1
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.来那度胺、伊沙佐米和地塞米松联合治疗多发性骨髓瘤。
N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282.
2
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.达雷妥尤单抗单药治疗治疗难治性多发性骨髓瘤患者（SIRIUS）：一项开放标签、随机、2 期试验。
Lancet. 2016 Apr 9;387(10027):1551-1560. doi: 10.1016/S0140-6736(15)01120-4. Epub 2016 Jan 7.
3
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.来那度胺联合化疗与自体移植，随后来那度胺联合泼尼松与来那度胺维持治疗多发性骨髓瘤患者：一项随机、多中心、3 期试验。
Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.
4
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.硼替佐米在家中给药治疗多发性骨髓瘤具有成本效益，并且相较于在医院给药，患者更倾向于这种方式：一项前瞻性单中心研究的结果。
Ann Oncol. 2016 Feb;27(2):314-8. doi: 10.1093/annonc/mdv563. Epub 2015 Nov 16.
5
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen.骨髓瘤自体干细胞移植后的微小残留病：对预后的影响独立于诱导方案。
Haematologica. 2016 Feb;101(2):e69-71. doi: 10.3324/haematol.2015.128215. Epub 2015 Oct 15.
6
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.Daratumumab 单药治疗多发性骨髓瘤中针对 CD38。
N Engl J Med. 2015 Sep 24;373(13):1207-19. doi: 10.1056/NEJMoa1506348. Epub 2015 Aug 26.
7
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.来那度胺和伏立诺他在多发性骨髓瘤自体移植后的维持治疗
Br J Haematol. 2015 Oct;171(1):74-83. doi: 10.1111/bjh.13527. Epub 2015 Jun 8.
8
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.依鲁替尼联合来那度胺和地塞米松治疗复发/难治性多发性骨髓瘤的疗效和安全性：一项多中心、开放标签的 II 期研究
N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.
9
Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?自体移植后多发性骨髓瘤的巩固和维持治疗：我们目前的状况如何？
Bone Marrow Transplant. 2015 Aug;50(8):1024-9. doi: 10.1038/bmt.2015.83. Epub 2015 Apr 20.
10
Evidence of long-term disease control with panobinostat maintenance in patients with relapsed multiple myeloma.复发多发性骨髓瘤患者使用帕比司他维持治疗实现长期疾病控制的证据。
Haematologica. 2015 Jul;100(7):e289-91. doi: 10.3324/haematol.2015.124164. Epub 2015 Mar 20.
Zotero 插件